Flagship explainer
What drives Anika Therapeutics, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$10.9M | FY2025 |
| |
| Income before tax | −$9.3M | FY2025 |
|
| Operating income | −$11.1M | FY2025 |
|
| $113M | FY2025 |
| |
| Ending assets | $190M | FY2025 |
|
| Beginning assets | $203M | FY2024 |
|
| $143M | FY2025 |
| |
| $154M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001171843-26-001275